摘要
目的：探讨美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎（UC）的临床疗效及对患者TNF-α、IL-8及IL-10水平的影响。方法：选择2013年1月~2014年1月我院收治的UC患者60例,随机分为研究组与对照组,每组30例。对照组患者应用美沙拉嗪治疗,研究组在此基础上联合双歧三联活菌治疗。观察两组临床疗效、血清TNF-α、IL-8及IL-10水平变化及药物不良反应。结果：研究组治疗的总有效率为86.67%,显著高于对照组的63.33%（P〈0.05）;治疗后,两组TNF-α、IL-8水平显著降低,IL-10水平显著升高（均P〈0.01）,研究组TNF-α、IL-8显著低于对照组,IL-10水平显著高于对照组（均P〈0.05）;研究组不良反应发生率为6.67%,明显低于对照组的33.33%（P〈0.05）。结论：美沙拉嗪联合双歧三联活菌对UC患者黏膜的保护作用显著,且有效抑制UC相关的炎性反应,安全可靠,适于临床推广与应用。
Objective： To explore the clinical efficacy of Mesalamine combined with Bifid Triple Viable in the treatment of patients with ulcerative colitis（UC） and its impact on levels of TNF- α, IL-8 and IL-10 of UC patients. Methods： A total of 60 UC patients, who were admitted to Chengdu Fifth People＇s Hospital of Sichuan Province from January 2013 to January 2014, were randomly divided into study group（n=30） and control group（n=30）. The patients in the control group were treated with Mesalamine, based on control group ＇s therapy, the patients of the study group were added Bifid Triple Viable, observing the clinical efficacy, serum IL-8, IL-10 and TNF-α levels, and adverse reaction of the two groups. Results： The total effectiveness（86.67%） of the study group was significantly higher than that（63.33%） of control group（P〈0.05）. After treatment, the levels of TNF-α and IL-8 of the two groups significantly decreased, while IL-10 levels, increased（all P〈0.01）; levels of TNF-α and IL-8 in the study group were significantly lower than those of the control group, IL-10 level, higher than that of the control group（all P〈0.05）. The rate of adverse reaction（6.67%） in the study group was significantly lower than that（33.33%） of the control group（P〈0.05）. Conclusion： Mesalamine combined with Bifid Triple Viable can effectively protect the mucosa of patients with UC,and inhibit the inflammatory response in UC, which is safe, reliable and suitable for clinical application.
出处
《现代生物医学进展》
CAS
2015年第23期4534-4536,共3页
Progress in Modern Biomedicine
